These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7910717)

  • 1. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease.
    Perfetti V; Bellotti V; Maggi A; Arbustini E; De Benedetti F; Paulli M; Marinone MG; Merlini G
    Am J Hematol; 1994 Jul; 46(3):189-93. PubMed ID: 7910717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.
    Ikeda S; Chisuwa H; Kawasaki S; Ozawa J; Hoshii Y; Yokota T; Aoi T
    J Clin Pathol; 1997 Nov; 50(11):965-7. PubMed ID: 9462253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission of nephrotic syndrome after removal of localized Castleman's disease.
    Keven K; Nergizoğlu G; Ateş K; Erekul S; Orhan D; Ertürk S; Tulunay O; Karatan O; Ertuğ AE
    Am J Kidney Dis; 2000 Jun; 35(6):1207-11. PubMed ID: 10845836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nephrotic Syndrome Caused by AA Amyloidosis Secondary to Unicentric Castleman's Disease:Report of One Case].
    You RL; Wen YB; Wang J; Ma J; Chen LM; Li XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Jun; 44(3):540-544. PubMed ID: 35791957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission of nephrotic syndrome due to AA amyloidosis and initiation of glomerular repair after surgical resection of localized Castleman's disease.
    Mandreoli M; Casanova S; Vianelli N; Pasquali S; Zucchelli P
    Nephron; 2002 Mar; 90(3):336-40. PubMed ID: 11867955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A 21-year-old male patient with nephrotic syndrome and "idiopathic" AA amyloidosis].
    Saura IM; Carretón A; López Guillén E; Alegría MS; Jimeno García L; Ferri B
    Nefrologia; 2004; 24 Suppl 3():109-12. PubMed ID: 15219083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End-stage renal failure from renal amyloidosis of the AA type associated with giant lymph node hyperplasia (Castleman's disease).
    Montoli A; Minola E; Stabile F; Grillo C; Radaelli L; Spanti D; Luccarelli E; Spata C; Minetti L
    Am J Nephrol; 1995; 15(2):142-6. PubMed ID: 7733151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Castleman's disease with nephrotic syndrome, amyloidosis and autoimmune manifestations.
    Curioni S; D'Amico M; Quartagno R; Martino S; Dell'Antonio G; Cusi D
    Nephrol Dial Transplant; 2001 Jul; 16(7):1475-8. PubMed ID: 11427644
    [No Abstract]   [Full Text] [Related]  

  • 9. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.
    Ogita M; Hoshino J; Sogawa Y; Sawa N; Katori H; Takemoto F; Ubara Y; Hara S; Miyakoshi S; Takaichi K
    Clin Nephrol; 2007 Sep; 68(3):171-6. PubMed ID: 17915620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary amyloidosis associated with Castleman's disease.
    Tanaka K; Horita M; Shibayama H; Seike M; Itoh Y; Hamaguchi K; Sato Y; Sakata T; Ishida T
    Intern Med; 1995 Feb; 34(2):122-6. PubMed ID: 7727877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary (AA) amyloidosis associated with Castleman's disease. Report of two cases and review of the literature.
    Ordi J; Grau JM; Junqué A; Nomdedeu B; Palacin A; Cardesa A
    Am J Clin Pathol; 1993 Oct; 100(4):394-7. PubMed ID: 8213634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrillary glomerulonephritis in Castleman's disease.
    Miadonna A; Salmaso C; Palazzi P; Elli A; Braidotti P; Lambertenghi Deliliers G
    Leuk Lymphoma; 1998 Jan; 28(3-4):429-35. PubMed ID: 9517516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman's disease.
    Shimojima Y; Takei Y; Tazawa K; Gono T; Fushimi T; Matsuda M; Hoshii Y; Ikeda S
    Amyloid; 2006 Sep; 13(3):184-6. PubMed ID: 17062386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castleman's disease with renal amyloidosis and nephrotic syndrome.
    Arinsoy T; Yilmaz M; Ataoğlu O; Bali M; Sindel S
    Nephrol Dial Transplant; 1997 Dec; 12(12):2713-6. PubMed ID: 9430878
    [No Abstract]   [Full Text] [Related]  

  • 15. Localised plasma-cell type Castleman's disease and AA-amyloidosis cured by resection. A case report and review of the literature.
    Verbrugghe W; Maes BD; Knockaert DC
    Acta Clin Belg; 2005; 60(1):22-7. PubMed ID: 15981701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease.
    Lachmann HJ; Gilbertson JA; Gillmore JD; Hawkins PN; Pepys MB
    QJM; 2002 Apr; 95(4):211-8. PubMed ID: 11937647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman's disease.
    Paydas S; Gonlusen G; Sagliker Y
    Nephron; 1995; 71(4):463-4. PubMed ID: 8587630
    [No Abstract]   [Full Text] [Related]  

  • 18. Interleukin-6-producing thymic squamous cell carcinoma associated with Castleman's disease and nephrotic syndrome.
    Matsumura N; Shiiki H; Saito N; Uramoto H; Hanatani M; Nonaka H; Nakamura S
    Intern Med; 2002 Oct; 41(10):871-4. PubMed ID: 12413013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Systemic AA amyloidosis induced by benign neoplasms].
    Bestard Matamoros O; Poveda Monje R; Ibernon Vilaró M; Carrera Plans M; Grinyó Boira JM
    Nefrologia; 2008; 28(1):93-8. PubMed ID: 18336138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?
    Seida A; Wada J; Morita Y; Baba M; Eguchi J; Nishimoto N; Okino T; Ichimura K; Yoshino T; Makino H
    Am J Kidney Dis; 2004 Jan; 43(1):E3-9. PubMed ID: 14712466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.